Berkeley N Limketkai, MD
Gastroenterology · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 8
Offices
8 locations · The Regents of the University of California · 1,426 clinicians in this group
Hospitals listed: Ronald Reagan UCLA Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Limketkai’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A132318 · Current
Licensed to practise in California · since 2014 · expires 2028-03-31 · University of Cincinnati College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Ronald Reagan UCLA Medical CenterLos Angeles, CAAcute Care Hospital · Government - State · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Jonsson Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.27 (4.69 to 7.85) · 3,570 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 5.17 (1.78 to 8.56) · 1,778 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.21 (0 to 0.62) · 8,165 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.59, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.611, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.503, Oct 2024 – Sep 2025
See every measure and the patient survey for Ronald Reagan UCLA Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.27 (4.69 to 7.85) · 3,570 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.17 (1.78 to 8.56) · 1,778 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 0.62) · 8,165 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.59 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.611 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.503 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.67 (0 to 1.44) · 2,883 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.7 to 1.09) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.14 (139.88 to 202.41) · 282 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 122 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 49 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.5 · 107 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 350 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.1 · 436 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.8 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.4 · 3,004 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 9,102 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.09 to 0.44) · 10,460 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0.57 to 2.77) · 1,972 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.27 to 3.44) · 3,000 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.93 (3.76 to 8.09) · 2,101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.65 (1.31 to 3.98) · 1,032 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.56 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.626 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 138 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 357 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -7.1 · 122 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -12.9 · 385 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 13.6 · 427 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 404 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.7 to 6.5) · 609 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (10.1 to 15) · 609 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.8 · 119 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.5 to 13.7) · 2,701 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,463 cases | No different | Jan 2024 – Dec 2024 |
What patients said (814 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$6,804
Medicare paid this office $6,804 for 31 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 14 | $1,933 | $102 |
Procedures Medicare counted
| Colonoscopy | 16 | More than 45% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
31 Original Medicare patients in 2024. Average age 67 · Women 58% · Also on Medicaid 36% · Health risk score 1.79. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 68% · Diabetes 35% · Depression 35%.
The office billed $75,365, Medicare allowed $9,366 and paid $6,804; for 61 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 31 | 61 | 67 | 1.79 | $75,365 | $6,804 |
| 2023 | 52 | 97 | 65 | 1.62 | $141,255 | $12,432 |
| 2022 | 73 | 121 | 67 | 1.49 | $170,464 | $14,842 |
| 2021 | 118 | 226 | 69 | 3.20 | $250,173 | $25,782 |
| 2020 | 84 | 164 | 70 | 2.88 | $132,072 | $18,462 |
| 2019 | 83 | 152 | 67 | 2.30 | $134,557 | $16,006 |
| 2018 | 143 | 321 | 66 | 2.48 | $237,204 | $31,331 |
| 2017 | 152 | 383 | 67 | 2.47 | $249,750 | $35,036 |
| 2016 | 146 | 292 | 66 | 2.25 | $215,500 | $30,695 |
| 2015 | 163 | 332 | 67 | 2.14 | $273,385 | $37,846 |
| 2014 | 14 | 19 | 65 | 1.58 | $19,483 | $2,322 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 14 | $2,261 | $113 |
| Biopsy of large bowel using a flexible endoscope | 17 | $2,174 | $128 |
2022: 4 services
| Biopsy of large bowel using a flexible endoscope | 21 | $2,845 | $135 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 11 | $2,198 | $200 |
| Long return visit (40+ min) | 12 | $1,911 | $136 |
| Return visit (30+ min) | 13 | $1,710 | $95 |
2021: 6 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,113 | $173 |
| Long return visit (40+ min) | 15 | $2,534 | $141 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 11 | $2,446 | $222 |
| Return visit (30+ min) | 13 | $1,967 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,552 | $62 |
| Biopsy of large bowel using a flexible endoscope | 15 | $1,504 | $100 |
2020: 3 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,579 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,780 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,557 | $92 |
2019: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,116 | $92 |
| New patient visit (60+ min) | 12 | $1,872 | $156 |
| Long return visit (40+ min) | 12 | $1,427 | $110 |
| Return visit (30+ min) | 12 | $953 | $73 |
2018: 9 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,933 | $122 |
| Long return visit (40+ min) | 17 | $2,594 | $96 |
| Diagnostic exam of large bowel using a flexible endoscope | 14 | $2,161 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,153 | $94 |
| Long return visit (40+ min) | 17 | $2,090 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $850 | $65 |
| Return visit (30+ min) | 11 | $777 | $60 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 22 | $101 | $5 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 11 | $48 | $4 |
2017: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $6,544 | $93 |
| Long return visit (40+ min) | 29 | $4,610 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,441 | $122 |
| New patient visit (60+ min) | 16 | $2,405 | $150 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $2,203 | $116 |
| Biopsy of large bowel using a flexible endoscope | 14 | $2,064 | $147 |
| Return visit (30+ min) | 21 | $1,834 | $71 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,324 | $102 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $987 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $972 | $65 |
| Short return visit (20+ min) | 12 | $593 | $42 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 35 | $182 | $5 |
2016: 7 services
| Long return visit (40+ min) | 35 | $5,265 | $96 |
| Return visit (30+ min) | 26 | $2,196 | $63 |
| New patient visit (60+ min) | 18 | $2,174 | $121 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,143 | $119 |
| Biopsy of large bowel using a flexible endoscope | 13 | $1,901 | $146 |
| New patient visit (45+ min) | 13 | $1,470 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $882 | $63 |
2015: 10 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $4,028 | $122 |
| Long return visit (40+ min) | 21 | $3,670 | $99 |
| Biopsy of large bowel using a flexible endoscope | 19 | $3,614 | $190 |
| New patient visit (60+ min) | 18 | $2,582 | $143 |
| New patient visit (45+ min) | 21 | $2,419 | $115 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $2,313 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,235 | $93 |
| Return visit (30+ min) | 25 | $2,175 | $68 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,441 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,426 | $65 |
Drugs they prescribed that Part D paid
$1,689,482
Pharmacies billed $1,689,482 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 141) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
58 generic and 83 brand-name prescriptions · $1,689,482 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stelara | 45 | $1,215,744 | $27,017 |
| Humira(Cf) | 16 | $232,352 | $14,522 |
| Mesalamine | 23 | $7,600 | $330 |
Year by year
| 2024 | 141 | 29 | 0% (0) | 59% | $1,689,482 |
| 2023 | 133 | 33 | 0% (0) | 62% | $1,441,336 |
| 2022 | 133 | 67 | 0% (0) | 59% | $1,033,644 |
| 2021 | 108 | 54 | 0% (0) | 44% | $303,214 |
| 2020 | 39 | 11 | 0% (0) | 49% | $176,513 |
| 2019 | 108 | 26 | 0% (0) | 53% | $290,340 |
| 2018 | 251 | 69 | 0% (0) | 49% | $261,669 |
| 2017 | 195 | 52 | 0% (0) | 37% | $155,998 |
| 2016 | 214 | 50 | 0% (0) | 43% | $152,809 |
| 2015 | 136 | 52 | 0% (0) | 47% | $72,133 |
| 2014 | 13 | None | 0% (0) | None | $439 |
| 2013 | 15 | None | 0% (0) | 0% | $464 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Stelara | 38 | $1,000,794 | $26,337 |
| Humira(Cf) | 18 | $264,399 | $14,689 |
| Mesalamine | 16 | $8,454 | $528 |
2022: 4 drugs
| Stelara | 30 | $774,163 | $25,805 |
| Mesalamine | 12 | $6,572 | $548 |
| Gavilyte-G | 22 | $301 | $14 |
| Peg-3350 and Electrolytes | 13 | $154 | $12 |
2021: 1 drug
| Gavilyte-C | 12 | $148 | $12 |
2019: 2 drugs
| Humira(Cf) | 11 | $117,348 | $10,668 |
| Lactated Ringers | 13 | $274 | $21 |
2018: 6 drugs
| Humira | 18 | $118,497 | $6,583 |
| Budesonide Ec | 18 | $13,772 | $765 |
| Hydrocortisone | 11 | $1,146 | $104 |
| Lactated Ringers | 46 | $813 | $18 |
| Peg 3350-Electrolyte | 18 | $291 | $16 |
| Prednisone | 14 | $118 | $8 |
2017: 4 drugs
| Humira | 18 | $101,383 | $5,632 |
| Polyethylene Glycol 3350 | 18 | $1,269 | $70 |
| Peg 3350-Electrolyte | 14 | $211 | $15 |
| Omeprazole | 13 | $78 | $6 |
2016: 6 drugs
| Humira | 17 | $105,224 | $6,190 |
| Pentasa | 13 | $10,940 | $842 |
| Dexilant | 13 | $3,233 | $249 |
| Esomeprazole Magnesium | 13 | $1,280 | $98 |
| Loperamide | 15 | $287 | $19 |
| Omeprazole | 11 | $217 | $20 |
2015: 3 drugs
| Pentasa | 14 | $6,061 | $433 |
| Peg 3350-Electrolyte | 18 | $339 | $19 |
| Pantoprazole | 17 | $235 | $14 |
Money from drug and device companies
$74,572 in 2025
| 2025 | 1 | 56 | $64,225 | $74,572 |
| 2024 | 1 | 19 | $18,419 | $20,384 |
| 2023 | 2 | 4 | None | $456 |
| 2022 | 2 | 2 | None | $190 |
| 2020 | 1 | 1 | None | $22 |
| 2019 | 1 | 6 | None | $152 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $74,572 | 56 payments
|
See all 56 published payments
| Janssen Biotech | Paid to speak or teach · 2025-12-06 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-12-02 | Tremfya | $149 |
| Janssen Biotech | Travel · 2025-11-24 | Tremfya | $291 |
| Janssen Biotech | Paid to speak or teach · 2025-11-22 | Tremfya | $4,900 |
| Janssen Biotech | Meals · 2025-11-19 | Tremfya | $125 |
| Janssen Biotech | Travel · 2025-11-19 | Tremfya | $265 |
| Janssen Biotech | Travel · 2025-11-19 | Tremfya | $166 |
| Janssen Biotech | Paid to speak or teach · 2025-11-08 | Tremfya | $4,900 |
| Janssen Biotech | Paid to speak or teach · 2025-11-08 | Tremfya | $4,900 |
| Janssen Biotech | Meals · 2025-11-06 | Tremfya | $146 |
| Janssen Biotech | Travel · 2025-11-05 | Tremfya | $293 |
| Janssen Biotech | Travel · 2025-11-05 | Tremfya | $1,842 |
| Janssen Biotech | Travel · 2025-11-05 | Tremfya | $152 |
| Janssen Biotech | Meals · 2025-11-05 | Tremfya | $125 |
| Janssen Biotech | Travel · 2025-10-27 | Tremfya | $310 |
| Janssen Biotech | Paid to speak or teach · 2025-10-25 | Stelara | $1,400 |
| Janssen Biotech | Paid to speak or teach · 2025-10-25 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-10-21 | Tremfya | $114 |
| Janssen Biotech | Paid to speak or teach · 2025-10-18 | Tremfya | $4,900 |
| Janssen Biotech | Travel · 2025-10-15 | Tremfya | $417 |
| Janssen Biotech | Meals · 2025-10-15 | Tremfya | $150 |
| Janssen Biotech | Travel · 2025-10-15 | Tremfya | $189 |
| Janssen Biotech | Travel · 2025-09-02 | Tremfya | $352 |
| Janssen Biotech | Paid to speak or teach · 2025-08-23 | Tremfya | $4,900 |
| Janssen Biotech | Travel · 2025-08-20 | Tremfya | $255 |
| Janssen Biotech | Travel · 2025-08-20 | Tremfya | $240 |
| Janssen Biotech | Meals · 2025-08-20 | Tremfya | $132 |
| Janssen Biotech | Paid to speak or teach · 2025-08-16 | Tremfya | $1,400 |
| Janssen Biotech | Paid to speak or teach · 2025-07-05 | Stelara | $875 |
| Janssen Biotech | Paid to speak or teach · 2025-06-06 | Tremfya | $66 |
| Janssen Biotech | Paid to speak or teach · 2025-05-31 | Tremfya | $1,400 |
| Janssen Biotech | Travel · 2025-05-28 | Tremfya | $147 |
| Janssen Biotech | Travel · 2025-05-28 | Tremfya | $171 |
| Janssen Biotech | Paid to speak or teach · 2025-05-24 | Tremfya | $3,150 |
| Janssen Biotech | Paid to speak or teach · 2025-05-24 | Tremfya | $4,900 |
| Janssen Biotech | Travel · 2025-05-22 | Tremfya | $268 |
| Janssen Biotech | Meals · 2025-05-22 | Tremfya | $143 |
| Janssen Biotech | Meals · 2025-05-20 | Tremfya | $150 |
| Janssen Biotech | Travel · 2025-05-20 | Tremfya | $740 |
| Janssen Biotech | Paid to speak or teach · 2025-05-17 | Tremfya | $7,700 |
| Janssen Biotech | Paid to speak or teach · 2025-05-03 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-04-29 | Tremfya | $130 |
| Janssen Biotech | Meals · 2025-04-11 | Tremfya | $57 |
| Janssen Biotech | Meals · 2025-04-11 | Tremfya | $150 |
| Janssen Biotech | Meals · 2025-04-11 | Tremfya | $32 |
| Janssen Biotech | Meals · 2025-04-11 | Tremfya | $38 |
| Janssen Biotech | Travel · 2025-04-10 | Tremfya | $194 |
| Janssen Biotech | Travel · 2025-04-10 | Tremfya | $669 |
| Janssen Biotech | Meals · 2025-04-10 | Tremfya | $100 |
| Janssen Biotech | Paid to speak or teach · 2025-03-22 | Tremfya | $3,128 |
| Janssen Biotech | Travel · 2025-03-12 | Tremfya | $634 |
| Janssen Biotech | Paid to speak or teach · 2025-02-28 | Tremfya | $3,128 |
| Janssen Biotech | Meals · 2025-02-27 | Tremfya | $146 |
| Janssen Biotech | Paid to speak or teach · 2025-02-01 | Tremfya | $3,128 |
| Janssen Biotech | Travel · 2025-01-29 | Tremfya | $740 |
| Janssen Biotech | Meals · 2025-01-29 | Tremfya | $124 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $20,384
| Janssen Biotech | Tremfya | $20,384 | 19 payments
|
2023: $456
| Nestle Healthcare Nutrition | None | $310 | 3 payments
|
| Janssen Biotech | Stelara | $147 | 1 payment
|
2022: $190
| Boston Scientific | Resolution Clip | $161 | 1 payment
|
| Abbvie | Skyrizi | $29 | 1 payment
|
2020: $22
| AbbVie | Humira | $22 | 1 payment
|
2019: $152
| Takeda Pharmaceuticals U.S.A. | Entyvio | $152 | 6 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 86.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1962609636
- Licence
- CA A132318California A132318: Current · expires 2028-03-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Internal medicine (207R00000X)
- Mailing address
- 5767 W Century Blvd Ste 400, Los Angeles, CA, 90045
- NPI first listed
- 2007-06-27
- NPI last updated
- 2019-09-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Drive, Stanford, CA, 94305